Premium
A phase II study of radiofrequency ablation of unresectable metastatic colorectal cancer with hepatic arterial infusion pump chemotherapy
Author(s) -
Martin Robert C.G.,
Scoggins Charles R.,
Mc Masters Kelly M.
Publication year - 2006
Publication title -
journal of surgical oncology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.201
H-Index - 111
eISSN - 1096-9098
pISSN - 0022-4790
DOI - 10.1002/jso.20463
Subject(s) - medicine , radiofrequency ablation , chemotherapy , colorectal cancer , hepatic arterial infusion , adjuvant , adverse effect , surgery , gastroenterology , cancer , ablation
Background Adjuvant hepatic arterial infusion (HAI) chemotherapy has been demonstrated to improve disease‐free survival for colorectal cancer liver metastases. It is unclear if this improvement can be extrapolated to unresectable liver metastases that undergo RFA. The aim of this study was to evaluate the combination of RFA and HAI chemotherapy for unresectable liver metastases. Methods Phase II study was conducted from November 2000 to July 2003 evaluating the use of complete extirpation by RFA, or resection/ablation with adjuvant HAI consisting of FUDR for 6 months. Results Twenty‐one patients had successful resection and/or RFA with HAI pump, which included treatment for 100 liver metastases (22 resected, 78 ablated; mean 4.8 tumors/patient). Four of 21 patients completed the full 6‐month course of HAI. Six of these patients had 12 adverse events related to HAIP, most commonly elevated liver enzymes. After a median follow‐up of 24 months, the median liver specific disease‐free and overall survival rates for the entire group were 17 and 30 months, respectively. Conclusions Given the complications and toxicity associated with HAI pump chemotherapy, adjuvant HAI chemotherapy after RFA of liver metastases may not be warranted as a first line treatment option. J. Surg. Oncol. 2006;93:387–393. © 2006 Wiley‐Liss, Inc.